Gonadal effects of a mouse Denys-Drash syndrome mutation.

Patek, C E; Saunders, P T K; Miles, C G; Berry, R L; Hastie, N D; Sharpe, R M; Hooper, M L

Patek, C E; Saunders, P T K; Miles, C G; Berry, R L; Hastie, N D; Sharpe, R M; Hooper, M L.

Affiliation

Patek CE; Sir Alastair Currie Cancer Research UK Laboratories, Molecular Medicine Centre, Western General Hospital, Crewe Road, EH4 2XU Edinburgh, UK.

Transgenic Res ; 14(5): 691-702, 2005 Oct.

Article in En | MEDLINE | ID: mdl-16245160

Subject(s)

Denys-Drash Syndrome/genetics; Denys-Drash Syndrome/pathology; Testis/pathology; WT1 Proteins/genetics; Animals; Anti-Mullerian Hormone; Chimera/genetics; Denys-Drash Syndrome/metabolism; Disease Models, Animal; Female; Gene Expression; Glycoproteins/genetics; Heterozygote; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Mutation; Receptors, Androgen/genetics; Sertoli Cells/metabolism; Sertoli Cells/pathology; Sex Ratio; Testicular Hormones/genetics; Testis/metabolism

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Testis / Denys-Drash Syndrome / WT1 Proteins Type of study: Prognostic_studies Limits: Animals Language: En Year: 2005 Type: Article

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Testis / Denys-Drash Syndrome / WT1 Proteins Type of study: Prognostic_studies Limits: Animals Language: En Year: 2005 Type: Article